Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019158 (
hepatitis
)
30,205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In a randomised, controlled study, the efficacy and safety of an indigenously developed azathioprine formulation, Azoran/1000 (Searle), was compared with an imported formulation
Imuran
, as an immunosuppressive agent in fresh cases of renal transplantation. All 14 patients enrolled into the trial completed the study period were analysed. There were 8 episodes of rejection, 4 in each group. All these cases responded to pulse steroids. There was no instance of severe bone marrow suppression or
hepatitis
in either group and none of the patients had any drug related adverse effects. The results of this study show that Azoran is equiefficacious and safe as an immunosuppressive drug in renal transplants and compares satisfactorily in all respects with the imported formulation
Imuran
and has the added advantage of being easily available and less costly.
...
PMID:Evaluation of the efficacy and safety of azathioprine (Azoran), in fresh cases of renal homotransplantation. 181 2
DST provides excellent graft survival in one- and zero-haplotype-matched donor-recipient pairs as well as a trend towards improving graft survival in HLA-identical matches; serum creatinine levels are good in functioning grafts;
Imuran
coverage does appear to decrease DST sensitization to the blood donor in nonsensitized patients undergoing a first transplant, which encourages early DST and transplantation in this group; flow cytometry has been extremely helpful in excluding subliminal anti-class 1 antigen activity in patients with positive B warm crossmatches alone; DST, in itself, does not appear to preclude subsequent cadaveric transplantation in patients sensitized to their blood donor; and the family history of the blood donor is known, with essentially no risk to the recipients of
hepatitis
, AIDS, etc. In regards to the issue of whether DST or Cs is better, both have merits, and one must be aware of the circumstances that relate to the optimum application of each therapy. Only a prospective study of DST- and Cs-treated patients with a long-term follow-up will probably resolve the issue of the optimum regimen for one-haplotype-matched living related donor-recipient pairs. The ultimate strategy may involve the selective use of each regimen for the most appropriate circumstances.
...
PMID:Donor-specific blood transfusions versus cyclosporine--the DST story. 354 13
The effect of Silymarin (Legalon) upon liver lesions was investigated using four experimental models: In acute galactosamine-
hepatitis
, Silymarin administration achieved protection of the liver structure (electron-microscopy included), liver cell glycogen, RNA and enzymatic activity, Galactosamine-depressed gluconeogenesis in the isolated perfused rat liver was significantly preserved by Silymarin treatment. In lead and cadmium poisoning the structural damage and histochemical and histoenzymatic changes were partly but significantly prevented. The complex noxious effects of
Imuran
overdoses were favourably influenced by Silymarin, without diminishing the cytostatic-immunosuppressive action of
Imuran
.
...
PMID:Effect of silymarin on experimental liver lesions. 733 95
Thiopurine drugs, azathioprine (
Imuran
) and 6-mercaptopurine (6-MP), are immunomodulators that have been shown to be effective at inducing and maintaining remission in inflammatory bowel disease. Although usually well-tolerated, the occurrence of side effects, typically myelotoxicity and hepatotoxicity, is a major drawback. The side effects can be classified as dose-dependent and independent. Both cholestatic
hepatitis
and endothelial injury, leading to vascular congestion and nodular regenerative hyperplasia, have been described during therapy with thiopurines, which can end up with portal hypertension. These injuries are potentially mediated by different metabolites. In this article we present a case of hyperammonaemic encephalopathy during therapy with 6-MP, possibly the first recorded in the literature, which probably resulted from the combination of thiopurine-induced liver injury with portal hypertension and the presence of spontaneous portosystemic venous shunts.
...
PMID:[Thiopurine-induced hyperammonaemic encephalopathy in a patient with Crohn's disease]. 2333 Feb 62